Vimarsana
Biggest News Aggregation in the World

Page 5 - Synact Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Synact Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Synact Pharma Today - Breaking & Trending Today

Notice of annual general meeting in SynAct Pharma AB - Vimarsana News

Notice of annual general meeting in SynAct Pharma AB

Election of auditor. Resolution on guidelines for remuneration to senior executives. Resolution on authorization for the board of directors regarding issues. Closing of the meeting. Item 1: Election of Chairman of the meeting Shareholders together representing approximately 20 per cent of the shares and votes in the company (the “Proposers”) propose that lawyer Ola Grahn is elected as chairman of the meeting or, in his absence, the person appointed by the board of directors instead. Item 2: Preparation and approval of the register of voters The register of voters that is proposed to be ap...

Source: realtid.se
SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Swedish version published 08:00 today - Vimarsana News

SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Swedish version published 08:00 today

Sponsrat Sponsrat SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Swedish version published 08:00 today SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a price of SEK 50 per share (the “Directed Share Issue”). Due to the Directed Share Issue being multiple times over-subscribed by a large number of professional investors, the gross proceeds in the Directed Share...

Source: realtid.se
SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Vimarsana News

SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version

Sök SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Swedish version published 08:00 today SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a price of SEK 50 per share (the “Directed Share Issue”). Due to the Directed Share Issue being multiple times over-subscribed by a large number of professional investors, the gross proceeds in the Directed Share Issue were increased from the SEK ...

Source: di.se
SynAct explores the conditions for carrying out a directed share issue - English version - Vimarsana News

SynAct explores the conditions for carrying out a directed share issue - English version

SynAct explores the conditions for carrying out a directed share issue - English version - Published today 17.31 CET SynAct Pharma AB (publ) (“SynAct” or “the Company”) has engaged ABG Sundal Collier AB to explore the conditions for carrying out a directed share issue of up to SEK 55 million based on an accelerated bookbuilding procedure. SynAct Publicerad: 4 februari 2021, 17:54 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN,...

Source: di.se
SynAct Pharma names Thomas Boesen as Chief Operating Officer - Vimarsana News

SynAct Pharma names Thomas Boesen as Chief Operating Officer

SynAct Pharma names Thomas Boesen as Chief Operating Officer SynAct Pharma AB (“SynAct”) today announced the appointment of Dr. Thomas Boesen as Chief Operating Officer (COO), effective immediately. His operational role as the new COO will be to drive forward the company’s three trials in clinical development with lead compound AP1189. Uppdaterad 2021-01-26 Publicerad 2021-01-26 Dr. Boesen has more than 20 years’ experience in the biotech and pharma industry. With a PhD in bioorganic chemistry from Copenhagen University, studies at...

Source: realtid.se